Study Summaries

Study summaries are free for everyone to read. Requires registration for free account of GYOEDU

Cervical Cancer

• Early Disease

  • SHAPE Trial: Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
  • CONCERV Trial: Conservative Surgery in Early-Stage Cervical Cancer
  • LANDONI Trial
  • GOG 92: Sedlis Criteria Study

• Sentinel Lymph Nodes

  • SENTICOL 1: Sentinel LND in Cervical Cancer
  • SENTICOL 2: Quality of Life in SLND Cervical Cancer
  • SENTIREC: Sentinel LND in Cervical Cancer Denmark Cohort

• Locally Advanced Disease

  • EORTC-55994: Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
  • UTERUS-11:Surgical versus clinical staging before primary chemoradiation
  • Tata Memorial Hospital Trial: Neoadjuvant Chemo + Rad Hyst Vs. Standard ChemoRT
  • OUTBACK Trial: Chemotherapy after Chemoradiation
  • KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
  • CALLA: Durvalumab versus placebo with chemoradiotherapy
  • Interlace Trial: Induction Chemotherapy prior to Chemoradition for Locally Advanced Cervical Cancer

• Recurrent/Metastatic Disease

  • GOG 240: Bevacizumab in Cervical Cancer
  • Tisotumab in Cervical Cancer: InnovaTV 204/ GOG-3023/ENGOT-cx6 Phase 2 trial
  • Tisotumab in Cervical Cancer: InnovaTV 301/ENGOT-cx12/GOG-3057 Phase 3 trial
  • Immunotherapy Trials
    • BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer
    • KEYNOTE-826: Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    • COMPASSION 16: Cadonilimab for persistent, recurrent, or metastatic cervical cancer
    • CHECKMATE 0358-Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer

Endometrial Cancer

• Surgical Trials

  • GOG 33: Surgical Pathologic Spread Patterns of Endometrial Cancer
  • GOG-LAP2: Laparoscopy Compared With Laparotomy for Endometrial Cancer Staging
  • LACE trial: Laparoscopy vs. Open for Endometrial Cancer
  • Sentinel Lymph Nodes
    • Fires Trial: Sentinel LND in Endometrial Cancer
    • Sentor Trial: Sentinel LND in High-Grade Endometrial Cancer

• High-Risk

  • PORTEC 1: EBRT vs. Observation in Endometrial Cancer
  • GOG 249: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer
  • PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk
  • Keynote B-21: Pembrolizumab vs. Placebo in High-risk Endometrial Cancer

• Advanced/Recurrent Disease

  • GOG 122:RT vs. Chemo in Endometrial Cancer
  • GOG 209: Carboplatin and Paclitaxel for Advanced Endometrial Cancer
  • GOG 238: Radiation With or Without Cisplatin in Locally Recurrent Endometrial Cancer
  • GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
  • PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer
  • GOG 261: Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Carcinosarcoma
  • NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
  • SIENDO Trial: Selinexor in TP53wt Advanced or Recurrent Endometrial Cancer
  • Immunotherapy Trials
    • Upfront therapy
      • NRG GY018: Pembrolizumab in Advanced Endometrial Cancer
      • RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
      • DUO-E trial: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib
      • LEAP-001: Pembro/Lenvima vs. Carbo/Taxol in upfront setting
    • Recurrence
      • KEYNOTE 775: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

• Hormonal/Targeted Therapy Trials

  • Phase II prospective Trial of Levonorgestrel IUD
  • GOG 3007: Megace Tamoxifen vs Letrozole Everolimus

Ovarian Cancer

• Early Stage Disease

  • Early Stage Ovarian Cancer Trials List
  • ACTION Trial: 10 year followup

• Surgical trials

  • PDS vs. NACT Trials
    • EORTC NACT vs. PDS Trial
    • CHORUS Trial: PDS vs. NACT
    • SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer
  • Secondary debulking trials
    • DESKTOP Trial - Secondary Debulking Surgery
    • SOC-1 Trial

• Upfront treatment trial

  • GOG 158: Carbo/Taxol vs. Cis/Taxol

  • MITO-7: Weekly chemotherapy in ovarian cancer

  • SCOTROC: Carboplatin and Taxotere in Ovarian Cancer

  • Dose-Dense therapy trials

    • JGOG 3016: Weekly dose-dense taxol in ovarian cancer
    • GOG 262: Weekly dose-dense chemotherapy with or without Bev
    • ICON 8: Weekly dose-dense chemotherapy in first-line epithelial ovarian

  • Intraperitoneal therapy and HIPEC trials

    • GOG 172: IP chemotherapy
    • GOG 252: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
    • OV-HIPEC 1: Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
    • Korean HIPEC trial
    • Korean HIPEC trial - IDS only 2023
    • CHIPOR Trial: Secondary Debulking and HIPEC in PSOC

  • PARP Maintenance Trials

    • SOLO 1: Olarparib in BRCA mutated patients
    • PRIMA: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
    • PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
    • PAOLA-1:Overall Survival Data

  • PARPs as Treatment Trials in Recurrence

    • ARIEL 4: Rucaprib vs. Chemotherapy

  • Bevacizumab Trials

    • GOG 218 (coming soon)
    • ICON 7 (coming soon)

• Recurrent treatment trials

  • Platinum-Sensitive Disease
    • CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol
  • Platinum-Resistant Disease
    • MIRASOL: Mirvetuximab in Platinum Resistant Cancer
    • MITO 23: Trabectedin Monotherapy vs. Physician's Choice Chemotherapy

• Bevacizumab Trials

  • GOG 213: Maintenance Bevacizumab in Platinum Sensitive Recurrence
  • OCEANS Trial: Bevacizumab Maintenance in Platinum Sensitive Recurrence
  • MITO 16B/MANGO-OV2/ENGOT-OV17: Bev Maintenance with Platinum Doublets in Platinum-sensitive Recurrence

• Low-Grade Ovarian

  • GOG 281: Trametinib in recurrent low-grade serous ovarian cancer
  • MILO/ENGOT-OV11: Binimetanib in low-grade serous ovarian cancer

• Mucinous Ovarian Cancer

  • GOG 241: Capecitabine/Oxaliplatin vs. Carboplatin/Taxol in Mucinous Ovarian Cancer

Vulvar Cancer

• Sentinel Nodes
  • GOG 173: SLND in Vulvar Cancer
• Locally Advanced Disease
  • GROINS V II:Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node
  • GOG 205: Chemoradiation for Locally Advanced Vulvar Cancer
  • GOG 279: Cisplatin, Gemcitabine, and IMRT for Locally Advanced Vulvar Carcinoma

Sarcoma

• PALETTE study: Pazopanib in Sarcoma
• GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma
• GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas
• LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma

Old Study Summaries

To access old study summaries submitted by volunteers, click here:

Study Summaries as an Airtable (full window)